Blueprint Medicines Corp (BPMC)
93.00
+2.27
(+2.50%)
USD |
NASDAQ |
Apr 26, 16:00
93.14
+0.14
(+0.16%)
After-Hours: 20:00
Blueprint Medicines Revenue (Quarterly): 71.96M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 71.96M |
| September 30, 2023 | 56.57M |
| June 30, 2023 | 57.57M |
| March 31, 2023 | 63.29M |
| December 31, 2022 | 38.78M |
| September 30, 2022 | 65.98M |
| June 30, 2022 | 36.55M |
| March 31, 2022 | 62.73M |
| December 31, 2021 | 107.02M |
| September 30, 2021 | 24.19M |
| June 30, 2021 | 27.30M |
| March 31, 2021 | 21.58M |
| December 31, 2020 | 34.11M |
| September 30, 2020 | 745.12M |
| June 30, 2020 | 8.343M |
| March 31, 2020 | 6.167M |
| December 31, 2019 | 51.53M |
| September 30, 2019 | 9.139M |
| Date | Value |
|---|---|
| June 30, 2019 | 5.11M |
| March 31, 2019 | 0.73M |
| December 31, 2018 | 1.033M |
| September 30, 2018 | 1.095M |
| June 30, 2018 | 41.44M |
| March 31, 2018 | 0.954M |
| December 31, 2017 | 1.628M |
| September 30, 2017 | 8.068M |
| June 30, 2017 | 5.89M |
| March 31, 2017 | 5.84M |
| December 31, 2016 | 7.691M |
| September 30, 2016 | 6.16M |
| June 30, 2016 | 7.065M |
| March 31, 2016 | 6.856M |
| December 31, 2015 | 4.635M |
| September 30, 2015 | 3.426M |
| June 30, 2015 | 2.687M |
| March 31, 2015 | 0.652M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
5.11M
Minimum
Jun 2019
745.12M
Maximum
Sep 2020
78.58M
Average
38.78M
Median
Dec 2022
Revenue (Quarterly) Benchmarks
| Alnylam Pharmaceuticals Inc | 439.72M |
| Apellis Pharmaceuticals Inc | 146.38M |
| Ionis Pharmaceuticals Inc | 324.50M |
| Madrigal Pharmaceuticals Inc | -- |
| Sarepta Therapeutics Inc | 396.78M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -110.92M |
| Total Expenses (Quarterly) | 177.11M |
| EPS Diluted (Quarterly) | -1.82 |
| Enterprise Value | 5.223B |
| Gross Profit Margin (Quarterly) | 99.64% |
| Profit Margin (Quarterly) | -154.1% |
| Earnings Yield | -8.99% |
| Normalized Earnings Yield | -8.989 |